Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.

Publication Type:

Journal Article

Source:

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume 52, Issue 10, p.1212-7 (2011)

Keywords:

2011, Administration, Intravaginal, Adolescent, Adult, Bacterial Load, Center-Authored Paper, Double-Blind Method, Female, Genomics Core Facility, Humans, Lactobacillus, Placebos, Polymerase Chain Reaction, Probiotics, RECURRENCE, RNA, Ribosomal, 16S, Shared Resources, Treatment Outcome, Urinary Tract Infections, Urine, Vaccine and Infectious Disease Division, Vagina, Young Adult

Abstract:

Urinary tract infections (UTIs) are common among women and frequently recur. Depletion of vaginal lactobacilli is associated with UTI risk, which suggests that repletion may be beneficial. We conducted a double-blind placebo-controlled trial of a Lactobacillus crispatus intravaginal suppository probiotic (Lactin-V; Osel) for prevention of recurrent UTI in premenopausal women.